Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Oral Solid Dosage Contract Manufacturing Market Value Expansion And Long-Term Growth Outlook
The market for contract manufacturing of oral solid dosage forms has experienced robust expansion lately, with projections indicating a rise from $42.39 billion in 2025 to $45.59 billion by 2026, reflecting a compound annual growth rate of 7.6%. This growth trajectory during the preceding period was influenced by several key factors, including heightened efforts to curb internal production expenses, the escalating intricacy of oral solid dosage drug formulations, a surge in the output of generic medications, constraints on the manufacturing capabilities of pharmaceutical firms, and an increasing dependency on external contract manufacturing organizations.
The marketplace for the contract manufacturing of oral solid pharmaceutical forms is poised for significant expansion in the upcoming years, projecting a rise to $59.05 billion by 2030, driven by a compound annual growth rate of 6.7%. This predicted upswing is underpinned by several key factors: an escalating need for adaptable and scalable pharmaceutical production processes, a widening array of new oral solid drug candidates in development pipelines, increased financial commitment to sophisticated manufacturing technologies, the broader adoption of pharmaceutical outsourcing practices in developing economies, and a heightened requirement for adaptable and swift production capacities. Dominant currents shaping this sector throughout the projected period encompass a greater tendency for pharmaceutical firms to delegate the manufacturing of oral solid dosage forms, a surge in the requirement for producing tablets and capsules in large quantities at competitive price points, a growing embrace of oral solid dosage formulations featuring modified and sustained release mechanisms, an intensified emphasis on adhering to regulatory standards and ensuring robust quality assurance within contract manufacturing operations, and a growing inclination towards comprehensive manufacturing and packaging solutions that cover the entire production lifecycle.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16137&type=smp
Oral Solid Dosage Contract Manufacturing Market Growth Factors Supporting Long-Term Expansion
The expanding appetite for generic medications is anticipated to be a primary catalyst for the advancement of the contract manufacturing sector focused on oral solid dosage forms. Generic drugs, recognized for their sameness to branded counterparts in terms of dosage, potency, safety, effectiveness, quality, and intended application, are seeing increased uptake due to factors such as expiring patents, the imperative for cost reduction, supportive regulatory policies, and broader access to healthcare services. Contract manufacturers specializing in oral solid dosage forms play a crucial role in facilitating the creation and dissemination of these generic medicines, offering expertise that boosts operational effectiveness, curtails expenses, guarantees superior product quality, and accelerates market entry. Illustrating this trend, the U.S. Food and Drug Administration noted in 2025 that it had sanctioned over 35,000 distinct generic drugs, with statistics indicating that nine out of every ten prescriptions are fulfilled using generic options. Additionally, the FDA’s proactive approach in November 2024 led to the issuance of more than 800 updated Product-Specific Guidances (PSGs) tailored for immediate-release solid oral generic drug products, further underscoring the supportive environment for generics and consequently fueling the expansion of the oral solid dosage contract manufacturing market.
Oral Solid Dosage Contract Manufacturing Market Segment Outlook: Which Categories Are Expanding The Fastest?
The oral solid dosage contract manufacturing market covered in this report is segmented –
1) By Product Type: Tablets, Capsules, Powders, Granules, Other Product Types
2) By Service: Drug Product Development, Fill Finish Product Manufacturing, API Manufacturing, Packaging And Labelling, Other Applications
3) By Therapeutic Area: Oncology, Cardiovascular Diseases, Metabolic Disorders, Neurological Disorders, infectious Diseases, Gastrointestinal Diseases, Other Therapeutic Areas
4) By End User: Large Size Companies, Medium And Small Size Companies
Subsegments:
1) By Tablets: Compressed Tablets, Effervescent Tablets, Chewable Tablets, Coated Tablets, Sustained Or Controlled Release Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Vegetarian Capsules, Liquid-Filled Capsules, Delayed Release Capsules
3) By Powders: Powders For Oral Suspension, Powders For Direct Compression, Powders For Mixing Or Blending, Instant Dissolving Powders
4) By Granules: Granules For Direct Compression, Granules For Tabletting, Effervescent Granules, Delayed Or Controlled Release Granules
5) By Other Product Types: Lozenges, Oral Strips, Oral Thin Films, Effervescent Tablets Or Granules
Oral Solid Dosage Contract Manufacturing Market Industry Trends Shaping Future Revenue Growth
Leading players within the oral solid dosage contract manufacturing sector are strategically investing in pioneering advancements, exemplified by the implementation of continuous manufacturing lines, as a means to solidify their market standing. This approach entails establishing production environments or systems designed to employ continuous manufacturing methodologies for pharmaceutical and similar goods. As an illustration, by January 2023, WuXi STA, a pharmaceutical entity based in China, introduced its inaugural continuous manufacturing line specifically for oral solid pharmaceutical goods. This state-of-the-art facility represents a substantial leap forward in pharmaceutical production, harnessing the benefits of continuous manufacturing to boost the overall efficiency, quality standards, and adaptability inherent in drug production workflows, thereby enabling quicker project completion and minimizing operational interruptions, ultimately expediting the availability of essential medicines to those in need.
Oral Solid Dosage Contract Manufacturing Market Key Companies And Competitive Benchmarking
Major companies operating in the oral solid dosage contract manufacturing market are Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under CordenPharma, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation, NextPharma AB, Delpharm, PCI Pharma Services, Adare Pharma, Skyepharma
Access The Complete Oral Solid Dosage Contract Manufacturing Market Report:
Oral Solid Dosage Contract Manufacturing Market Leading Geography: Which Region Generates The Most Revenue?
Asia-Pacificwas the largest region in the oral solid dosage contract manufacturing market in 2025. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model